Want to see HK:1643 full AI Analyst Report?
1643 Stock Chart & Stats
HK$0.51
<HK$0.01(1.54%)
At close: 4:00 PM EST
HK$0.51
<HK$0.01(1.54%)
Day’s Range― - ―
52-Week RangeHK$0.49 - HK$3.26
Previous CloseN/A
Volume456.00K
Average Volume (3M)639.13K
Market Cap
HK$712.80M
Enterprise ValueHK$583.30M
Total Cash (Recent Filing)HK$229.81M
Total Debt (Recent Filing)HK$69.03K
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding720,000,000
10 Day Avg. Volume382,100
30 Day Avg. Volume639,133
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.61
Price to Sales (P/S)2.14
P/FCF Ratio-18.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetExtremely low debt and a high balance-sheet score provide durable financial flexibility. This reduces solvency risk, supports funding working capital, R&D or product registrations, and gives management time to execute a turnaround without urgent refinancing pressure over the next several months.
Core Cash-generation AbilityPositive operating cash flow in 2025 and prior years' strong cash generation show the business can convert sales into cash when operations stabilize. That enduring cash-conversion capacity supports near-term liquidity and funds operational recovery without immediate reliance on external capital if trends improve.
Proven Historical Margins And Earnings PowerA track record of high margins and profitability across 2020–2022 indicates the underlying product economics and operating model can be profitable. This structural capability suggests management can regain margin health if demand, pricing or mix normalize and fixed costs are leveraged back.
Bears Say
Steep Revenue DeclineA ~30% revenue drop and ongoing multi-year decline materially reduces scale and pricing leverage. Lower top-line volume erodes gross profit and makes fixed costs harder to cover, creating durable headwinds to margin recovery and requiring structural fixes in distribution, product mix or demand generation.
Profitability Deterioration And Negative ROEA swing to net losses and compressing gross margins signals structural margin pressure and weak capital monetization. Negative ROE means the equity base is not producing returns, limiting reinvestment capacity and increasing the risk that management must cut costs or seek external capital to stabilize operations.
Volatile And Negative Free Cash FlowRecent negative free cash flow following prior strong years points to weaker cash conversion or higher discretionary/working-capital outflows. Sustained FCF deficits reduce balance-sheet cushions, constrain strategic spending and raise financing risk if negative trends persist over the next several months.
Modern Chinese Medicine Group Co. Ltd. News
1643 FAQ
What was Modern Chinese Medicine Group Co. Ltd.’s price range in the past 12 months?
Modern Chinese Medicine Group Co. Ltd. lowest stock price was HK$0.48 and its highest was HK$3.26 in the past 12 months.
What is Modern Chinese Medicine Group Co. Ltd.’s market cap?
Modern Chinese Medicine Group Co. Ltd.’s market cap is HK$712.80M.
When is Modern Chinese Medicine Group Co. Ltd.’s upcoming earnings report date?
Modern Chinese Medicine Group Co. Ltd.’s upcoming earnings report date is Aug 20, 2026 which is in 13 days.
How were Modern Chinese Medicine Group Co. Ltd.’s earnings last quarter?
Modern Chinese Medicine Group Co. Ltd. released its earnings results on Mar 30, 2026. The company reported -HK$0.027 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.027.
Is Modern Chinese Medicine Group Co. Ltd. overvalued?
According to Wall Street analysts Modern Chinese Medicine Group Co. Ltd.’s price is currently Overvalued.
Does Modern Chinese Medicine Group Co. Ltd. pay dividends?
Modern Chinese Medicine Group Co. Ltd. pays a Notavailable dividend of HK$0.017 which represents an annual dividend yield of N/A. See more information on Modern Chinese Medicine Group Co. Ltd. dividends here
What is Modern Chinese Medicine Group Co. Ltd.’s EPS estimate?
Modern Chinese Medicine Group Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Modern Chinese Medicine Group Co. Ltd. have?
Modern Chinese Medicine Group Co. Ltd. has 720,000,000 shares outstanding.
What happened to Modern Chinese Medicine Group Co. Ltd.’s price movement after its last earnings report?
Modern Chinese Medicine Group Co. Ltd. reported an EPS of -HK$0.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.013%.
Which hedge fund is a major shareholder of Modern Chinese Medicine Group Co. Ltd.?
Currently, no hedge funds are holding shares in HK:1643
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Modern Chinese Medicine Group Co. Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
94.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.26%
Trailing 12-Months
Company Description
Modern Chinese Medicine Group Co. Ltd.
As an investment holding company, Modern Chinese Medicine Group Co., Ltd. manufactures and distributes traditional Chinese pharmaceutical products, primarily targeting the middle-aged and elderly populations across the People's Republic of China. Its extensive product line provides treatments for a wide array of health issues, including qi deficiency, blood stasis, cardiovascular and cerebrovascular conditions, digestive and gastrointestinal ailments, gynecological problems, as well as disorders affecting the respiratory and nervous systems. Established in 1986, the enterprise maintains its principal offices in Chengde, China, and operates as a subsidiary of Modern Biotechnology Group Holdings Co., Ltd.
Technical Analysis
Tong Ren Tang Technologies Co
―
Wai Yuen Tong Medicine Holdings Limited
―
Lee's Pharmaceutical Holdings Limited
―
PuraPharm Corp. Ltd.
―
Pak Fah Yeow International Limited
―